# Study to Assess the Adverse Events, Tolerability, and How Oral Doses of ABBV-932 Moves Through the Body in Healthy Adult Chinese Participants

> **NCT07024797** · PHASE1 · COMPLETED · sponsor: **AbbVie** · enrollment: 20 (actual)

## Conditions studied

- Healthy Volunteer

## Interventions

- **DRUG:** ABBV-932
- **DRUG:** Placebo for ABBV-932

## Key facts

- **NCT ID:** NCT07024797
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2025-08-21
- **Primary completion:** 2025-12-08
- **Final completion:** 2025-12-08
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2025-12-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07024797

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07024797, "Study to Assess the Adverse Events, Tolerability, and How Oral Doses of ABBV-932 Moves Through the Body in Healthy Adult Chinese Participants". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT07024797. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*